Does the media refer more to UTHR or REGN?

In the previous week, Regeneron Pharmaceuticals had 19 more articles in the media than United Therapeutics. MarketBeat recorded 33 mentions for Regeneron Pharmaceuticals and 14 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.65 beat Regeneron Pharmaceuticals' score of 0.48 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 13 Very Positive mention(s) 0 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to UTHR or ARGX?

In the previous week, United Therapeutics had 7 more articles in the media than argenex. MarketBeat recorded 14 mentions for United Therapeutics and 7 mentions for argenex. argenex's average media sentiment score of 1.27 beat United Therapeutics' score of 0.65 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to UTHR or NTRA?

In the previous week, Natera had 17 more articles in the media than United Therapeutics. MarketBeat recorded 31 mentions for Natera and 14 mentions for United Therapeutics. Natera's average media sentiment score of 0.74 beat United Therapeutics' score of 0.65 indicating that Natera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Natera 11 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to UTHR or RVMD?

In the previous week, Revolution Medicines had 1 more articles in the media than United Therapeutics. MarketBeat recorded 15 mentions for Revolution Medicines and 14 mentions for United Therapeutics. Revolution Medicines' average media sentiment score of 0.80 beat United Therapeutics' score of 0.65 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 7 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BIIB or UTHR?

In the previous week, United Therapeutics had 6 more articles in the media than Biogen. MarketBeat recorded 14 mentions for United Therapeutics and 8 mentions for Biogen. Biogen's average media sentiment score of 0.92 beat United Therapeutics' score of 0.65 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

United Therapeutics (UTHR) Competitors

$501.27 -10.45 (-2.04%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$501.29 +0.02 (+0.00%)

As of 08/13/2026 06:00 PM Eastern

Compare

UTHR vs. REGN, ARGX, NTRA, RVMD, and BIIB

Should you buy United Therapeutics stock or one of its competitors? United Therapeutics's main competitors and comparable companies include Regeneron Pharmaceuticals (REGN), argenex (ARGX), Natera (NTRA), Revolution Medicines (RVMD), and Biogen (BIIB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does United Therapeutics compare to Regeneron Pharmaceuticals?

United Therapeutics (NASDAQ:UTHR) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

In the previous week, Regeneron Pharmaceuticals had 19 more articles in the media than United Therapeutics. MarketBeat recorded 33 mentions for Regeneron Pharmaceuticals and 14 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.65 beat Regeneron Pharmaceuticals' score of 0.48 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	13 Very Positive mention(s)	0 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

United Therapeutics has a net margin of 41.56% compared to Regeneron Pharmaceuticals' net margin of 27.86%. United Therapeutics' return on equity of 20.18% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

United Therapeutics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market.

United Therapeutics presently has a consensus price target of $646.00, indicating a potential upside of 28.87%. Regeneron Pharmaceuticals has a consensus price target of $793.74, indicating a potential downside of 1.52%. Given United Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe United Therapeutics is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.62

Regeneron Pharmaceuticals has higher revenue and earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	6.76	$1.33B	$27.95	17.93
Regeneron Pharmaceuticals	$14.34B	5.79	$4.50B	$40.46	19.92

Summary

United Therapeutics beats Regeneron Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does United Therapeutics compare to argenex?

United Therapeutics (NASDAQ:UTHR) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by company insiders. Comparatively, 2.4% of argenex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

United Therapeutics has higher earnings, but lower revenue than argenex. United Therapeutics is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	6.76	$1.33B	$27.95	17.93
argenex	$4.25B	12.62	$1.29B	$26.04	32.91

United Therapeutics presently has a consensus price target of $646.00, indicating a potential upside of 28.87%. argenex has a consensus price target of $1,056.89, indicating a potential upside of 23.33%. Given United Therapeutics' higher possible upside, equities research analysts plainly believe United Therapeutics is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

United Therapeutics has a net margin of 41.56% compared to argenex's net margin of 32.19%. argenex's return on equity of 43.59% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
argenex	32.19%	43.59%	36.66%

United Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, argenex has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

In the previous week, United Therapeutics had 7 more articles in the media than argenex. MarketBeat recorded 14 mentions for United Therapeutics and 7 mentions for argenex. argenex's average media sentiment score of 1.27 beat United Therapeutics' score of 0.65 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

argenex beats United Therapeutics on 9 of the 17 factors compared between the two stocks.

How does United Therapeutics compare to Natera?

United Therapeutics (NASDAQ:UTHR) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

United Therapeutics has a net margin of 41.56% compared to Natera's net margin of -7.11%. United Therapeutics' return on equity of 20.18% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Natera	-7.11%	-11.82%	-8.19%

United Therapeutics currently has a consensus target price of $646.00, suggesting a potential upside of 28.87%. Natera has a consensus target price of $319.38, suggesting a potential upside of 2.77%. Given United Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe United Therapeutics is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 8.6% of United Therapeutics shares are held by insiders. Comparatively, 5.1% of Natera shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

United Therapeutics has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, Natera has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market.

United Therapeutics has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	6.76	$1.33B	$27.95	17.93
Natera	$2.31B	19.42	-$208.16M	-$1.36	N/A

In the previous week, Natera had 17 more articles in the media than United Therapeutics. MarketBeat recorded 31 mentions for Natera and 14 mentions for United Therapeutics. Natera's average media sentiment score of 0.74 beat United Therapeutics' score of 0.65 indicating that Natera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	11 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

United Therapeutics beats Natera on 10 of the 17 factors compared between the two stocks.

How does United Therapeutics compare to Revolution Medicines?

United Therapeutics (NASDAQ:UTHR) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

United Therapeutics has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	6.76	$1.33B	$27.95	17.93
Revolution Medicines	$11.58M	3,738.92	-$1.13B	-$8.82	N/A

In the previous week, Revolution Medicines had 1 more articles in the media than United Therapeutics. MarketBeat recorded 15 mentions for Revolution Medicines and 14 mentions for United Therapeutics. Revolution Medicines' average media sentiment score of 0.80 beat United Therapeutics' score of 0.65 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	7 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

United Therapeutics currently has a consensus price target of $646.00, suggesting a potential upside of 28.87%. Revolution Medicines has a consensus price target of $161.79, suggesting a potential downside of 19.91%. Given United Therapeutics' higher probable upside, equities research analysts plainly believe United Therapeutics is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.91

United Therapeutics has a net margin of 41.56% compared to Revolution Medicines' net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Revolution Medicines	N/A	-88.20%	-57.85%

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 8.6% of United Therapeutics shares are held by company insiders. Comparatively, 7.6% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

United Therapeutics beats Revolution Medicines on 9 of the 17 factors compared between the two stocks.

How does United Therapeutics compare to Biogen?

Biogen (NASDAQ:BIIB) and United Therapeutics (NASDAQ:UTHR) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

In the previous week, United Therapeutics had 6 more articles in the media than Biogen. MarketBeat recorded 14 mentions for United Therapeutics and 8 mentions for Biogen. Biogen's average media sentiment score of 0.92 beat United Therapeutics' score of 0.65 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

87.9% of Biogen shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

United Therapeutics has lower revenue, but higher earnings than Biogen. United Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$10.03B	3.10	$1.29B	$5.65	37.28
United Therapeutics	$3.18B	6.76	$1.33B	$27.95	17.93

Biogen has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Biogen presently has a consensus price target of $227.07, suggesting a potential upside of 7.80%. United Therapeutics has a consensus price target of $646.00, suggesting a potential upside of 28.87%. Given United Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe United Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has a net margin of 41.56% compared to Biogen's net margin of 8.32%. United Therapeutics' return on equity of 20.18% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
United Therapeutics	41.56%	20.18%	17.98%

Summary

United Therapeutics beats Biogen on 12 of the 17 factors compared between the two stocks.

Get United Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UTHR vs. The Competition

Export

Metric	United Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$21.95B	$3.74B	$7.07B	$12.99B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	17.93	10.24	269.63	25.21
Price / Sales	6.76	1,287.04	600.52	101.12
Price / Cash	15.51	103.01	70.53	50.75
Price / Book	3.36	17.84	13.17	6.24
Net Income	$1.33B	-$13.30M	$3.45B	$347.70M
7 Day Performance	-6.97%	0.61%	0.74%	0.87%
1 Month Performance	-4.82%	0.48%	1.41%	0.90%
1 Year Performance	60.63%	54.57%	67.05%	20.13%

United Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UTHR United Therapeutics	4.3665 of 5 stars	$501.27 -2.0%	$646.00 +28.9%	+61.8%	$21.95B	$3.18B	17.93	1,400	Insider Trade
REGN Regeneron Pharmaceuticals	3.7905 of 5 stars	$808.05 +3.0%	$797.75 -1.3%	+43.5%	$80.75B	$14.34B	19.97	15,410	Trending News Insider Trade
ARGX argenex	4.7175 of 5 stars	$866.11 +0.1%	$1,056.89 +22.0%	+32.5%	$54.12B	$4.25B	33.26	1,863
NTRA Natera	2.8781 of 5 stars	$318.35 -1.2%	$301.90 -5.2%	+97.1%	$46.13B	$2.31B	N/A	6,140	Analyst Forecast
RVMD Revolution Medicines	2.2156 of 5 stars	$206.97 +0.9%	$160.68 -22.4%	+460.4%	$43.97B	$11.58M	N/A	250	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UTHR) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

United Therapeutics (UTHR) Competitors

UTHR vs. REGN, ARGX, NTRA, RVMD, and BIIB

How does United Therapeutics compare to Regeneron Pharmaceuticals?

Summary

How does United Therapeutics compare to argenex?

Summary

How does United Therapeutics compare to Natera?

Summary

How does United Therapeutics compare to Revolution Medicines?

Summary

How does United Therapeutics compare to Biogen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR vs. The Competition

United Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

United Therapeutics (UTHR) Competitors

UTHR vs. REGN, ARGX, NTRA, RVMD, and BIIB

How does United Therapeutics compare to Regeneron Pharmaceuticals?

Does the media refer more to UTHR or REGN?

Do insiders and institutionals have more ownership in UTHR or REGN?

Is UTHR or REGN more profitable?

Which has more risk and volatility, UTHR or REGN?

Do analysts prefer UTHR or REGN?

Which has stronger earnings & valuation, UTHR or REGN?

Summary

How does United Therapeutics compare to argenex?

Do institutionals and insiders have more ownership in UTHR or ARGX?

Which has higher earnings and valuation, UTHR or ARGX?

Do analysts rate UTHR or ARGX?

Is UTHR or ARGX more profitable?

Which has more volatility & risk, UTHR or ARGX?

Does the media refer more to UTHR or ARGX?

Summary

How does United Therapeutics compare to Natera?

Is UTHR or NTRA more profitable?

Do analysts recommend UTHR or NTRA?

Do institutionals and insiders hold more shares of UTHR or NTRA?

Which has more risk and volatility, UTHR or NTRA?

Which has stronger valuation & earnings, UTHR or NTRA?

Does the media refer more to UTHR or NTRA?

Summary

How does United Therapeutics compare to Revolution Medicines?

Which has better earnings and valuation, UTHR or RVMD?

Does the media refer more to UTHR or RVMD?

Which has more risk and volatility, UTHR or RVMD?

Do analysts recommend UTHR or RVMD?

Is UTHR or RVMD more profitable?

Do insiders & institutionals hold more shares of UTHR or RVMD?

Summary

How does United Therapeutics compare to Biogen?

Does the media prefer BIIB or UTHR?

Do institutionals & insiders hold more shares of BIIB or UTHR?

Which has stronger earnings and valuation, BIIB or UTHR?

Which has more volatility and risk, BIIB or UTHR?

Do analysts rate BIIB or UTHR?

Is BIIB or UTHR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR vs. The Competition

United Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools